EntryPoint Capital LLC Sells 15,372 Shares of MiMedx Group, Inc $MDXG

EntryPoint Capital LLC decreased its stake in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 31.3% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 33,721 shares of the company’s stock after selling 15,372 shares during the period. EntryPoint Capital LLC’s holdings in MiMedx Group were worth $256,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Virtus Fund Advisers LLC bought a new stake in MiMedx Group during the fourth quarter worth approximately $35,000. Tower Research Capital LLC TRC grew its holdings in MiMedx Group by 77.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock valued at $63,000 after purchasing an additional 2,837 shares during the last quarter. Legato Capital Management LLC acquired a new position in MiMedx Group during the first quarter valued at approximately $101,000. Ameriprise Financial Inc. acquired a new position in MiMedx Group during the fourth quarter valued at approximately $115,000. Finally, Sowell Financial Services LLC acquired a new position in MiMedx Group during the first quarter valued at approximately $115,000. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Stock Up 4.0%

MDXG opened at $7.31 on Friday. MiMedx Group, Inc has a 1-year low of $5.47 and a 1-year high of $10.14. The company has a current ratio of 4.39, a quick ratio of 3.90 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of 34.81 and a beta of 1.79. The business has a 50 day moving average of $6.65 and a 200-day moving average of $7.09.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.04. MiMedx Group had a return on equity of 23.03% and a net margin of 8.84%.The company had revenue of $98.61 million during the quarter, compared to analysts’ expectations of $90.79 million. As a group, sell-side analysts anticipate that MiMedx Group, Inc will post 0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

MDXG has been the topic of several analyst reports. Cantor Fitzgerald increased their price target on MiMedx Group from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Thursday, July 31st. Wall Street Zen upgraded MiMedx Group from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 2nd. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $12.00.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.